Cargando…

Fidaxomicin Use in the Pediatric Population with Clostridioides difficile

Clostridioides difficile infection (CDI) remains a devastating infection both in hospital settings and in the community. While a number of antibiotics have anti-C. difficile activity, fidaxomicin is unique as a minimally absorbed antibiotic with narrow spectrum of activity. These features make it an...

Descripción completa

Detalles Bibliográficos
Autores principales: Oliver, Meredith B, Vaughn, Byron P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9514785/
https://www.ncbi.nlm.nih.gov/pubmed/36177387
http://dx.doi.org/10.2147/CPAA.S273318
_version_ 1784798345205645312
author Oliver, Meredith B
Vaughn, Byron P
author_facet Oliver, Meredith B
Vaughn, Byron P
author_sort Oliver, Meredith B
collection PubMed
description Clostridioides difficile infection (CDI) remains a devastating infection both in hospital settings and in the community. While a number of antibiotics have anti-C. difficile activity, fidaxomicin is unique as a minimally absorbed antibiotic with narrow spectrum of activity. These features make it an appealing option for pediatric CDI to balance safety and efficacy. The purpose of this structured review was to outline the clinical evidence for safety and efficacy of fidaxomicin for pediatric CDI. A structured literature search was performed to identify relevant clinical data. Fidaxomicin is similarly effective to oral vancomycin with a lower rate of recurrent CDI. There were no serious safety signals reported with fidaxomicin. In conclusion, fidaxomicin is a safe and effective treatment option for pediatric CDI.
format Online
Article
Text
id pubmed-9514785
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-95147852022-09-28 Fidaxomicin Use in the Pediatric Population with Clostridioides difficile Oliver, Meredith B Vaughn, Byron P Clin Pharmacol Review Clostridioides difficile infection (CDI) remains a devastating infection both in hospital settings and in the community. While a number of antibiotics have anti-C. difficile activity, fidaxomicin is unique as a minimally absorbed antibiotic with narrow spectrum of activity. These features make it an appealing option for pediatric CDI to balance safety and efficacy. The purpose of this structured review was to outline the clinical evidence for safety and efficacy of fidaxomicin for pediatric CDI. A structured literature search was performed to identify relevant clinical data. Fidaxomicin is similarly effective to oral vancomycin with a lower rate of recurrent CDI. There were no serious safety signals reported with fidaxomicin. In conclusion, fidaxomicin is a safe and effective treatment option for pediatric CDI. Dove 2022-09-23 /pmc/articles/PMC9514785/ /pubmed/36177387 http://dx.doi.org/10.2147/CPAA.S273318 Text en © 2022 Oliver and Vaughn. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Review
Oliver, Meredith B
Vaughn, Byron P
Fidaxomicin Use in the Pediatric Population with Clostridioides difficile
title Fidaxomicin Use in the Pediatric Population with Clostridioides difficile
title_full Fidaxomicin Use in the Pediatric Population with Clostridioides difficile
title_fullStr Fidaxomicin Use in the Pediatric Population with Clostridioides difficile
title_full_unstemmed Fidaxomicin Use in the Pediatric Population with Clostridioides difficile
title_short Fidaxomicin Use in the Pediatric Population with Clostridioides difficile
title_sort fidaxomicin use in the pediatric population with clostridioides difficile
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9514785/
https://www.ncbi.nlm.nih.gov/pubmed/36177387
http://dx.doi.org/10.2147/CPAA.S273318
work_keys_str_mv AT olivermeredithb fidaxomicinuseinthepediatricpopulationwithclostridioidesdifficile
AT vaughnbyronp fidaxomicinuseinthepediatricpopulationwithclostridioidesdifficile